As shown in Table 4, the principal ADR with study drugs were blood disorders related to thioguanine, pegaspargase and Erwinia asparaginase, infections with thioguanine, pegaspargase, Erwinia asparaginase and rituximab, and gastrointestinal or metabolic disorders with pegaspargase (additional information is available as Supplementary Material). Here, ASPG is linked to metabolic disease.